Cargando…

Establishment of a pancreatic cancer animal model using the pancreas-targeted hydrodynamic gene delivery method

This research developed an easy-to-use, reproducible pancreatic cancer animal model utilizing pancreas-targeted hydrodynamic gene delivery to deliver human pancreatic cancer-related genes to the pancreas of wild-type rats. KRAS(G12D)-induced pancreatic intraepithelial neoplasia lesions showed malign...

Descripción completa

Detalles Bibliográficos
Autores principales: Shibata, Osamu, Kamimura, Kenya, Tanaka, Yuto, Ogawa, Kohei, Owaki, Takashi, Oda, Chiyumi, Morita, Shinichi, Kimura, Atsushi, Abe, Hiroyuki, Ikarashi, Satoshi, Hayashi, Kazunao, Yokoo, Takeshi, Terai, Shuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018811/
https://www.ncbi.nlm.nih.gov/pubmed/35474735
http://dx.doi.org/10.1016/j.omtn.2022.03.019
Descripción
Sumario:This research developed an easy-to-use, reproducible pancreatic cancer animal model utilizing pancreas-targeted hydrodynamic gene delivery to deliver human pancreatic cancer-related genes to the pancreas of wild-type rats. KRAS(G12D)-induced pancreatic intraepithelial neoplasia lesions showed malignant transformation in the main pancreatic duct at 4 weeks and developed acinar-to-ductal metaplasia, which led to pancreatic ductal adenocarcinoma within 5 weeks, and the gene combination of KRAS(G12D) and YAP enhanced these effects. The repeat hydrodynamic gene delivery of KRAS(G12D) + YAP combination at 4 weeks showed acinar-to-ductal metaplasia in all rats and pancreatic ductal adenocarcinoma in 80% of rats 1 week later. Metastatic tumors in the liver, lymph nodes, and subcutaneous lesions and nervous invasion were confirmed. KRAS(G12D) and YAP combined transfer contributes to the E- to N-cadherin switch in pancreatic ductal adenocarcinoma cells and to tumor metastases. This pancreatic cancer model will speed up pancreatic cancer research for novel treatments and biomarkers for early diagnosis.